Nama's AI scorecard currently rates Astrana Health Hold (5.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ASTH's P/E ratio?

Astrana Health trades at a trailing price-to-earnings ratio of 12.9.

When does ASTH report earnings?

Astrana Health's next scheduled report is on Mar 1, 2027. Analysts expect EPS of $0.65.

What is the ASTH price target?

The median analyst price target from 9 analysts is $53.00, with a range of $41.00 – $65.00.

Is ASTH Shariah compliant?

Nama's AAOIFI-style screen reads Astrana Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Astrana Health (ASTH)

Healthcare · Medical Care Facilities · NASDAQ

Astrana Health (ASTH) is a Healthcare company in the Medical Care Facilities industry. It has a market capitalization of $1.71B, a trailing price-to-earnings ratio of 12.9 and a free-cash-flow yield of 6.1%. Over the most recent reported fiscal year, revenue grew 56.4% and free cash flow per share grew 129.9%. Nama's AI scorecard rates it Hold, 5.0 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Hold · 5.0/10

The sections balance. As of Nov 7, 2026.

Momentum

Middle · +11.3% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-74.1%

How far the last close sits under the highest price of the past five years.

Market cap	$1.71B
Trailing P/E	12.9
Price / book	2.0
Price / sales	0.5
FCF yield	6.1%
Dividend yield	—
Gross margin	10.5%
Operating margin	2.6%
Net margin	1.1%
Revenue growth (YoY)	+56.4%
Revenue growth (3-yr annual)	+40.6%
EPS growth (YoY)	+12.2%
FCF/share growth (YoY)	+129.9%
Beta	1.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Care Facilities

ASTH earnings

Next report: Mar 1, 2027 (Q4 2026, EPS estimate $0.65). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.71	$0.88	-19.3%	—
Q2 2026	Aug 6, 2026	$0.80	$0.73	+9.6%	$972.52M
Q1 2026	May 7, 2026	$0.74	$0.65	+13.8%	$965.10M
Q4 2025	Mar 2, 2026	$0.42	$0.33	+27.3%	$950.53M

ASTH analyst price target

Median target $53.00 from 9 analysts, ranging $41.00 – $65.00.

Medical Care Facilities peers

Ticker	Company	Market cap	P/E
HCA	HCA Healthcare	$103.40B	16.5
THC	Tenet Healthcare	$22.55B	12.7
EHC	Encompass Health	$13.50B	22.4
FMS	Fresenius Medical Care	$12.15B	10.2
DVA	DaVita	$12.04B	13.6
UHS	Universal Health Services	$11.52B	8.6
ENSG	Ensign Group	$10.56B	23.8
PACS	PACS Group	$7.87B	20.1

Explore live ASTH data on Nama Insights →

Recent Congressional trades

Astrana Health trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Judy Chu	House	Buy	$100,001 - $250,000	Aug 30, 2025

ASTH FAQ

Is ASTH a buy?: Nama's AI scorecard currently rates Astrana Health Hold (5.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ASTH's P/E ratio?: Astrana Health trades at a trailing price-to-earnings ratio of 12.9.
When does ASTH report earnings?: Astrana Health's next scheduled report is on Mar 1, 2027. Analysts expect EPS of $0.65.
What is the ASTH price target?: The median analyst price target from 9 analysts is $53.00, with a range of $41.00 – $65.00.
Is ASTH Shariah compliant?: Nama's AAOIFI-style screen reads Astrana Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.